Two for­mer Stan­ford re­searchers nab a $41M launch round to learn the se­crets of the ‘se­cre­tome’

A new start­up on the West Coast wants to tack­le chron­ic dis­eases and age-re­lat­ed con­di­tions, and it’s try­ing to do so us­ing the world of “se­cret­ed pro­teins.”

Ju­ve­na Ther­a­peu­tics emerged with a $41 mil­lion Se­ries A on Mon­day morn­ing, nab­bing Mubadala Cap­i­tal — the UAE’s sov­er­eign wealth fund — and Hori­zons Ven­tures as its lead in­vestors. A plat­form play, the biotech in­tends to use the funds pri­mar­i­ly to build out its map of the “se­cre­tome” while al­so ad­vanc­ing a hand­ful of dis­cov­ery-stage ex­per­i­men­tal drugs.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER